Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted ra...
SYDNEY, Oct. 16, 2024 /PRNewswire/ -- HIGHLIGHTS Cohort 4 - SECuRE Trial * The third participa...
Highlights * United States Food and Drug Administration (U.S. FDA) provided positive feedback on...
Highlights * Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67 Cu-SAR-bis...
SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...
Highlights * Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64 Cu-SAR-b...
SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...
HIGHLIGHTS * Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the ...
HIGHLIGHTS * Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67 Cu-SAR-bisPSMA in met...
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical sta...
SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...
Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67...
Highlights * Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in met...
SYDNEY, July 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company")...
Highlights * FDA agreement for a pivotal Phase III trial for 64Cu SAR-bisPSMA diagnostic in pros...
SYDNEY, June 28, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...
SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...
Highlights * Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic c...
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...